Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.53 |
| ▸ | ATP4A | P20648 | 4/20 | 0.51 |
| ▸ | ATP4B | P51164 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | HRH1 | P35367 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584441 | 0.83 | PDCD1 (0.50) | ATP4AATP4B | |
| SCHEMBL3578168 | 0.82 | HRH3 (0.55) | HRH3KCNH2HRH1 | |
| SCHEMBL3586344 | 0.82 | HRH3 (0.55) | HRH3KCNH2HRH1 | |
| SCHEMBL3581380 | 0.78 | HRH3 (0.57) | HRH3ATP4AATP4BKCNH2 | |
| SCHEMBL3582711 | 0.75 | HRH3 (0.56) | HRH3KCNH2HRH1 | |
| SCHEMBL3579620 | 0.75 | PPARD (0.43) | HRH3ATP4AATP4BHRH1 | |
| SCHEMBL3569806 | 0.75 | HRH3 (0.54) | HRH3KCNH2HRH1 | |
| SCHEMBL12490052 | 0.75 | PDCD1 (0.51) | — | |
| SCHEMBL3582333 | 0.74 | PDCD1 (0.45) | ATP4AATP4B | |
| SCHEMBL3668166 | 0.74 | HRH3 (0.48) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | claimed |
| EP-2049548-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | claimed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | claimed |
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | UCB PHARMA, S.A. (BE) | 2010-01-14 | — | — | US | disclosed |
| EP-2049548-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012010-A1 | FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS | UCB PHARMA, S.A. (BE) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009969-A1 | Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands | HRH3, HRH4, HRH2 | HRH3 1/4885ATP4A 1932/4885ATP4B 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.